SecurityTSLA / Tesla Motors, Inc. (88160R101)
IndustryMotor Vehicles and Passenger Car Bodies
Common Shares Outstanding170,593,144 shares (as of 2018-06-30)
Total Insiders18
Total Directors9
Total Officers10

Stock Insider Trading (from SEC Form 4)

Tesla Motors, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

TSLA / Tesla Motors, Inc. insiders include Gracias Antonio J., FIELD JOHN DOUGLAS, RICE LINDA JOHNSON MORTON DAVID H JR, Branderiz Eric, Musk Elon, Reichow Gregory, Buss Brad W, McNeill Jon, Ehrenpreis Ira Matthew, Guillen Jerome M, Jurvetson Stephen T, DENHOLM ROBYN M, MURDOCH JAMES R, and Ahuja Deepak, Musk Kimbal, Jason Wheeler S, Straubel Jeffrey B, .

Insider Roster

Insider Dir Off 10% Shares Owned
MORTON DAVID H JR Chief Accounting Officer
X 0
Musk Kimbal Director
X 148,333
FIELD JOHN DOUGLAS Senior VP, Engineering
X 18,264
MURDOCH JAMES R Director
X
RICE LINDA JOHNSON Director
X
Buss Brad W Director
X
Gracias Antonio J. Director
X
DENHOLM ROBYN M Director
X
Ehrenpreis Ira Matthew Director
X
Musk Elon CEO, Director, 10% Owner
X X X 33,737,921
Ahuja Deepak Chief Financial Officer
X 61,059
Branderiz Eric VP, Chief Accounting Officer
X 1,386
Straubel Jeffrey B Chief Technical Officer
X
McNeill Jon President, WW Sales/Service
X 2,612
Jurvetson Stephen T Director
X 104,243
Reichow Gregory VP, Production
X
Jason Wheeler S Chief Financial Officer
X
Guillen Jerome M VP Service and Sales Ops
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-07-02 4 Musk Kimbal S X D 360.569 -175 148,333 53,484,281
2018-07-02 4 Musk Kimbal S X D 359.633 -300 148,508 53,408,378
2018-07-02 4 Musk Kimbal S X D 358.555 -800 148,808 53,355,852
2018-07-02 4 Musk Kimbal S X D 357.337 -300 149,608 53,460,474
2018-07-02 4 Musk Kimbal S X D 355.67 -300 149,908 53,317,778
2018-07-02 4 Musk Kimbal M X D 29.66 1,875 150,208
2018-06-15 4 FIELD JOHN DOUGLAS S D 361.354 -400 18,264 6,599,769
2018-06-15 4 FIELD JOHN DOUGLAS S D 360.624 -397 18,664 6,730,686
2018-06-15 4 FIELD JOHN DOUGLAS S D 359.443 -1,003 19,061 6,851,343
2018-06-15 4 FIELD JOHN DOUGLAS S D 358.365 -900 20,064 7,190,235
2018-06-15 4 FIELD JOHN DOUGLAS S D 356.792 -300 20,964 7,479,787
2018-06-13 4 Musk Elon by Trust P I 347.001 4,626 33,737,921 11,707,092,325
2018-06-13 4 Musk Elon by Trust P I 346.637 6,032 33,733,295 11,693,208,179
2018-06-13 4 Musk Elon by Trust P I 344.957 2,114 33,727,263 11,634,455,463
2018-06-13 4 Musk Elon by Trust P I 343.791 2,431 33,725,149 11,594,402,700
2018-06-13 4 Musk Elon by Trust P I 342.782 2,297 33,722,718 11,559,540,721
2018-06-12 4 Musk Elon by Trust P I 344.829 3,468 33,720,421 11,627,779,053
2018-06-12 4 Musk Elon by Trust P I 343.855 14,509 33,716,953 11,593,742,874
2018-06-12 4 Musk Elon by Trust P I 342.775 37,023 33,702,444 11,552,355,242
2018-06-06 4 FIELD JOHN DOUGLAS F D 300.52 -758 21,264
2018-06-06 4 FIELD JOHN DOUGLAS F D 300.52 -265 22,022
2018-06-06 4 FIELD JOHN DOUGLAS F D 300.52 -281 22,287
2018-06-06 4 FIELD JOHN DOUGLAS F D 300.52 -95 22,568
2018-06-05 4 FIELD JOHN DOUGLAS M D 189 22,663
2018-06-05 4 FIELD JOHN DOUGLAS M D 1,520 22,474
2018-06-05 4 FIELD JOHN DOUGLAS M D 530 20,954
2018-06-05 4 FIELD JOHN DOUGLAS M D 563 20,424
2018-06-06 4 Ahuja Deepak F D 300.52 -1,329 61,059
2018-06-05 4 Ahuja Deepak M D 2,666 62,388
2018-05-07 4 Buss Brad W Buss Family Trust M I 28.43 4,666 13,348
2018-05-07 4 Gracias Antonio J. M D 28.43 16,666 293,163
2018-05-07 4 Musk Elon by Trust P I 302.133 6,133 33,665,421 10,171,434,643
2018-05-07 4 Musk Elon by Trust P I 301.376 3,000 33,659,288 10,144,101,580
2018-05-07 4 Musk Elon by Trust P I 300.012 4,358 33,656,288 10,097,290,275
2018-05-07 4 Musk Elon by Trust P I 299.252 739 33,651,930 10,070,407,356
2018-05-07 4 Musk Elon by Trust P I 298.01 4,514 33,651,191 10,028,391,430
2018-05-07 4 Musk Elon by Trust P I 297.151 3,508 33,646,677 9,998,143,717
2018-05-07 4 Musk Elon by Trust P I 296.311 4,845 33,643,169 9,968,841,050
2018-05-07 4 Musk Elon by Trust P I 295.028 5,903 33,638,324 9,924,247,453
2018-04-05 4 Musk Kimbal S X D 300.0 -1,875 148,333 44,499,900
2018-04-05 4 Musk Kimbal M X D 29.66 1,875 150,208
2017-11-06 4 Gracias Antonio J. by AJG Growth Fund J I 105 276,497
2018-03-16 4 FIELD JOHN DOUGLAS S X D 322.77 -100 19,861 6,410,535
2018-03-16 4 FIELD JOHN DOUGLAS S X D 321.87 -600 19,961 6,424,847
2018-03-16 4 FIELD JOHN DOUGLAS S X D 320.03 -300 20,561 6,580,137
2018-03-06 4 FIELD JOHN DOUGLAS F D 333.75 -1,258 20,861
2018-03-06 4 FIELD JOHN DOUGLAS F D 333.75 -196 22,119
2018-03-06 4 FIELD JOHN DOUGLAS F D 333.75 -184 22,315
2018-03-06 4 FIELD JOHN DOUGLAS F D 333.75 -78 22,499
2018-03-05 4 FIELD JOHN DOUGLAS M D 3,042 22,577
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
TSLA : Tesla Motors Stock Analysis and Research Report

2017-10-09 - Asif

Tesla Motors's mission is to accelerate the world’s transition to sustainable energy. The company design, develop, manufacture, lease and sell high-performance fully electric vehicles, solar energy generation systems and energy storage products. The company also offer maintenance, installation, operation and other services related to its products. Automotive Tesla Motors production vehicle fleet includes Model S premium sedan and Model X sport utility vehicle, which are its highest-performance and most capable vehicles, and beginning in July 2017, its Model 3, a lower priced sedan designed for the mass market. The company continue to enhance its vehicle offerings with enhanced Autopilot options, Internet connectivity and free over-the-air software updates. The company continually deploy its internally developed software into the vehicle fleet, depending on the hardware of the vehicle, to provide additional safety and convenience features. The company are also actively working ...

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Nvidia: Automotive AI Narrative Concerns Becoming A Serious Issue

7h seekingalpha
Nvidia's CEO once declared Tesla's autopilot as 5 years ahead of everyone when they selected their technology. Now, NVDA is being replaced by a seemingly basic in-house custom inference accelerator. (74-1)

Tesla - What Happens To Model S And X Sales In 2019?

8h seekingalpha
Tesla owners are underestimating the impact of the upcoming phase out of tax credits both in the US and overseas. (49-1)

Should You Buy Tesla Stock? 3 Pros, 3 Cons

10h investorplace
Elon Musk has been competing with the President of the United States for attention on Twitter (NYSE:TWTR) and now, his social media presence is actually beginning to impact Tesla (NASDAQ:TSLA) stock. After a 5% sell-off over five days, the stock’s year-to-date gains have been shaved to just 3%. (56-1)

Nobody Does It Better

14h seekingalpha
The U.S. stock market finally did it. Or did it? On Wednesday, August 22, the U.S. stock market as measured by the S&P 500 Index will become the longest bull market in history. Fantastic. Given how far we have come from the near destruction of the financial world so long ago now, what have we learned along the way to apply to the remainder of the journey that lies ahead? (56-0)

5 Reasons Why Ford Will End Up Cutting Its Dividend

14h seekingalpha
Ford is a recognizable name with a juicy dividend that yields more than 6%. This makes it an appetizing stock for dividend investors. (64-0)